The risk of venous thromboembolism in adult patients with diffuse glioma: a nationwide population-based study
DOI:
https://doi.org/10.2340/1651-226X.2024.40137Keywords:
Cancer-associated thrombosis, brain tumor, glioblastoma, epidemiology, risk factorsAbstract
Background and purpose: Venous thromboembolism (VTE) is a cause of increased morbidity and risk of death. Studies report VTE in up to 30% of glioma patients but the results vary. The VTE risk is relevant when evaluating prophylaxis to avoid unnecessary bleeding or overdiagnosis. This study examines the VTE incidence in patients with glioma WHO grade 2–4, and when VTE occurred, risk factors, and overall survival (OS) for patients with WHO grade 4.
Materials and methods: In total 3,630 patients with WHO grade 2 (n = 230), grade 3 (n = 317), and grade 4 (n = 3,083) gliomas from 2010 to 2018 were identified using the Danish Neuro-Oncology Registry. VTE diagnoses and time of death were obtained from Statistics Denmark.
Results and interpretation: The VTE incidence was 5.2, 6.3, and 6.8% in patients with WHO grade 2, 3, and 4 gliomas, respectively. The VTE incidence rate was highest during the first 3 months after the diagnosis with 53 events. Increasing age (HR 1.03, 95%CI 1.01–1.04), male sex (HR 1.47, 95%CI 1.09–1.99), poor performance status (HR 1.57, 95%CI 1.10–2.25), and post-operative long-course radiochemotherapy (HR 2.10, 95%CI 1.19–3.72) were predictors of VTE in patients with glioma WHO grade 4. There was no difference in OS comparing patients having VTE to those without (p = 0.068). In conclusion, patients with glioma WHO grade 2–4 were at high risk of VTE, especially the first 3 months after diagnosis. Increasing age, male sex, poor performance status, and long-course radiochemotherapy were associated with increased risk of VTE in patients with glioma WHO grade 4.
Downloads
References
Mulder FI, Horváth-Puhó E, van Es N, et al. Venous thromboembolism in cancer patients: a population-based cohort study. Blood. 2021;137:1959–69.
https://doi.org/10.1182/blood.2020007338 DOI: https://doi.org/10.1182/blood.2020007338
Diaz M, Jo J. Venous thrombotic events and anticoagulation in brain tumor patients. Curr Oncol Rep. 2022;24:493–500.
https://doi.org/10.1007/s11912-021-01178-9 DOI: https://doi.org/10.1007/s11912-021-01178-9
Jo J, Diaz M, Horbinski C, et al. Epidemiology, biology, and management of venous thromboembolism in gliomas: an interdisciplinary review. Neuro-Oncol. 2023;25(8):1381–94.
https://doi.org/10.1093/neuonc/noad059 DOI: https://doi.org/10.1093/neuonc/noad059
Diaz M, Jo J, Smolkin M, Ratcliffe SJ, Schiff D. Risk of venous thromboembolism in grade II–IV gliomas as a function of molecular subtype. Neurology. 2021;96:e1063–9.
https://doi.org/10.1212/WNL.0000000000011414 DOI: https://doi.org/10.1212/WNL.0000000000011414
Sawaya R, Zuccarello M, Elkalliny M, Nishiyama H. Postoperative venous thromboembo-lism and brain tumors: Part I. Clinical profile. J Neurooncol. 1992;14:119–25.
https://doi.org/10.1007/BF00177615 DOI: https://doi.org/10.1007/BF00177615
Muster V, Gary T. Contrasts in glioblastoma-venous thromboembolism versus bleeding risk. Cells. 2021;10(6):1414.
https://doi.org/10.3390/cells10061414 DOI: https://doi.org/10.3390/cells10061414
Morgan ER, Mason WP, Maurice C. A critical balance: managing coagulation in patients with glioma. Expert Rev Neurother. 2016;16:803–14.
https://doi.org/10.1080/14737175.2016.1181542 DOI: https://doi.org/10.1080/14737175.2016.1181542
Riedl J, Ay C. Venous thromboembolism in brain tumors: risk factors, molecular mecha-nisms, and clinical challenges. Semin Thromb Hemost. 2019;45:334–41.
https://doi.org/10.1055/s-0039-1688493 DOI: https://doi.org/10.1055/s-0039-1688493
Semrad TJ, O’Donnell R, Wun T, et al. Epidemiology of venous thromboembolism in 9489 patients with malignant glioma. J Neurosurg. 2007;106:601–8.
https://doi.org/10.3171/jns.2007.106.4.601 DOI: https://doi.org/10.3171/jns.2007.106.4.601
Burdett KB, Unruh D, Drumm M, et al. Determining venous thromboembolism risk in pa-tients with adult-type diffuse glioma. Blood. 2023;141:1322–36.
https://doi.org/10.1182/blood.2022017858 DOI: https://doi.org/10.1182/blood.2022017858
Streiff MB, Ye X, Kickler TS, et al. A prospective multicenter study of venous thromboem-bolism in patients with newly-diagnosed high-grade glioma: hazard rate and risk factors. J Neurooncol. 2015;124:299–305.
https://doi.org/10.1007/s11060-015-1840-z DOI: https://doi.org/10.1007/s11060-015-1840-z
Watanabe J, Natsumeda M, Okada M, et al. Podoplanin expression and IDH-wildtype sta-tus predict venous thromboembolism in patients with high-grade gliomas in the early postoperative period. World Neuro-surg. 2019;128:e982–8.
https://doi.org/10.1016/j.wneu.2019.05.049 DOI: https://doi.org/10.1016/j.wneu.2019.05.049
Mandel JJ, Youssef M, Yust-Katz S, et al. IDH mutation status and the development of ve-nous thromboembolism in astrocytoma patients. J Neurol Sci. 2021;427:117538.
https://doi.org/10.1016/j.jns.2021.117538 DOI: https://doi.org/10.1016/j.jns.2021.117538
Kaptein FHJ, Stals MAM, Kapteijn MY, et al. Incidence and determinants of thrombotic and bleeding complications in patients with glioblastoma. J Thromb Haemost. 2022;20:1665–73.
https://doi.org/10.1111/jth.15739 DOI: https://doi.org/10.1111/jth.15739
Simanek R, Vormittag R, Hassler M, et al. Venous thromboembolism and survival in pa-tients with high-grade glioma. Neuro Oncol. 2007;9:89–95.
https://doi.org/10.1215/15228517-2006-035 DOI: https://doi.org/10.1215/15228517-2006-035
Kapteijn MY, Kaptein FHJ, Stals MAM, et al. Targeted DNA sequencing to identify genetic aberrations in glioblastoma that underlie venous thromboembo-lism; a cohort study. Thromb Res. 2022;221:10–8.
https://doi.org/10.1016/j.thromres.2022.11.013 DOI: https://doi.org/10.1016/j.thromres.2022.11.013
Eisele A, Seystahl K, Rushing EJ, et al. Venous thromboembolic events in glioblastoma patients: an epidemiological study. Eur J Neurol. 2022;29:2386–97.
https://doi.org/10.1111/ene.15404 DOI: https://doi.org/10.1111/ene.15404
Lim G, Ho C, Roldan Urgoti G, Leugner D, Easaw J. Risk of venous thromboembolism in glioblastoma patients. Cureus. 2018;10:e2678.
https://doi.org/10.7759/cureus.2678 DOI: https://doi.org/10.7759/cureus.2678
Mir Seyed Nazari P, Riedl J, Preusser M, et al. Combination of isocitrate dehydrogenase 1 (IDH1) mutation and podoplanin expression in brain tumors identifies patients at high or low risk of venous thromboembo-lism. J Thromb Haemost. 2018;16:1121–7.
https://doi.org/10.1111/jth.14129 DOI: https://doi.org/10.1111/jth.14129
Fisher JL, Palmisano S, Schwartzbaum JA, Svensson T, Lönn S. Comorbid conditions as-sociated with glioblastoma. J Neurooncol. 2014;116:585–91.
https://doi.org/10.1007/s11060-013-1341-x DOI: https://doi.org/10.1007/s11060-013-1341-x
Hansen S, Nielsen J, Laursen RJ, et al. The Danish Neuro-Oncology Registry: establish-ment, completeness and validity. BMC Res Notes. 2016;9:425.
https://doi.org/10.1186/s13104-016-2233-x DOI: https://doi.org/10.1186/s13104-016-2233-x
Schmidt M, Pedersen L, Sørensen HT. The Danish Civil Registration System as a tool in epidemiology. Eur J Epidemiol. 2014;29:541–9.
https://doi.org/10.1007/s10654-014-9930-3 DOI: https://doi.org/10.1007/s10654-014-9930-3
Schmidt M, Schmidt SAJ, Sandegaard JL, Ehrenstein V, Pedersen L, Sørensen HT. The Danish National Patient Registry: a review of content, data quali-ty, and research potential. Clin Epidemiol. 2015;7:449–90.
https://doi.org/10.2147/CLEP.S91125 DOI: https://doi.org/10.2147/CLEP.S91125
Louis DN, Perry A, Wesseling P, et al. The 2021 WHO Classification of Tumors of the Cen-tral Nervous System: a summary. Neuro-Oncol. 2021;23:1231–51.
https://doi.org/10.1093/neuonc/noab106 DOI: https://doi.org/10.1093/neuonc/noab106
dnog.dk [Internet]. [Guidelines for treatment of intracranial gliomas in adults 2016] [cit-ed 27-04-2023]. Available from: https://www.dnog.dk/assets/files/Retningslinier%20PDF/DNOG%202016%20Gliom%20retningslinje%20final.pdf. Danish
dst.dk [Internet]. Access to data [cited 04-05-2023]. Available from: https://www.dst.dk/en/TilSalg/Forskningsservice/Dataadgang
Huang Y, Ding H, Luo M, et al. Combined analysis of clinical and laboratory markers to predict the risk of venous thromboembolism in patients with IDH1 wild-type glioblastoma. Support Care Cancer. 2022;30:6063–9.
https://doi.org/10.1007/s00520-022-07050-1 DOI: https://doi.org/10.1007/s00520-022-07050-1
Edwin NC, Khoury MN, Sohal D, McCrae KR, Ahluwalia MS, Khorana AA. Recurrent venous thromboembolism in glioblastoma. Thromb Res. 2016;137:184–8.
https://doi.org/10.1016/j.thromres.2015.11.027 DOI: https://doi.org/10.1016/j.thromres.2015.11.027
Zhang C, Deng Z, Yang Z, Xie J, Hou Z. A nomogram model to predict the acute venous thromboembolism risk after surgery in patients with glioma. Thromb Res. 2023;224:21–31.
https://doi.org/10.1016/j.thromres.2023.02.002 DOI: https://doi.org/10.1016/j.thromres.2023.02.002
Senders JT, Goldhaber NH, Cote DJ, et al. Venous thromboembolism and intracranial hemorrhage after craniotomy for primary malignant brain tumors: a National Surgical Quality Improvement Program analysis. J Neu-rooncol. 2018;136:135–45.
https://doi.org/10.1007/s11060-017-2631-5 DOI: https://doi.org/10.1007/s11060-017-2631-5
Maria S, Konstantin P, Vitaliy L, et al. Evaluating of existing VTE risk scales in glioma pa-tients. Clin Appl Thromb Hemost. 2024;30:10760296241238210.
https://doi.org/10.1177/10760296241238210 DOI: https://doi.org/10.1177/10760296241238210
Zhang F, Chiu Y, Ensor J, Mohamed MO, Peat G, Mamas MA. Elixhauser outperformed Charlson comorbidity index in prognostic value after ACS: in-sights from a national registry. J Clin Epidemiol. 2022;141:26–35.
https://doi.org/10.1016/j.jclinepi.2021.08.025 DOI: https://doi.org/10.1016/j.jclinepi.2021.08.025
Additional Files
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2023 Frederik R. Hovman, Frantz R. Poulsen, Steinbjørn Hansen, Rikke H. Dahlrot
This work is licensed under a Creative Commons Attribution 4.0 International License.
